An affiliate of the Georgia Institute of Technology, the Global Center for Medical Innovation (GCMI) helps verify, validate and accelerate commercialization of new medical technologies that save lives and improve patient care. From our Northyards and 14th Street facilities in midtown Atlanta, we help find the finish line for medtech innovations at any point on the pathway from bench to bedside.

Additionally, GCMI and T3 Labs proudly support BME Capstone teams with our medtech design, development and preclinical testing resources including facilities, staff, materials and know-how.

Principal investigators, faculty and student projects served include: Dr. Andres Garcia, Dr. Scott Hollister, Dr. Omer Inan, the Coulter Foundation, over 20 additional GT faculty members and dozens of BME Capstone teams.

This archive details just how we do that and to what effect.

Venture Funding for New, “University Bred” Medical Technologies: When It’s Time and What to Bring

If you’ve been following our funding series for innovators seeking to spin out new medical technologies from higher ed “environments” like Georgia Tech, you’ll have seen:   The Top 5 Medtech and Life Science Funding Resources for GT Faculty, Researchers and Investigators – at Phase Zero, THE Place to Start, and Follow-On, for University Sourced…

The GCMI 2023 State of Medtech Design and Development Report Part 2

In part 1 of our 2023 State of Medtech Design and Development Report we discussed sensors, AI and the paradigm shift in regulatory strategy.   Here in part 2, we dive into a persistent need for gap analysis, the importance of focusing on the unmet clinical need, the challenges of manufacturing at scale and investigate…

What to Do, Where to Go and Why for Newly Funded University-Based New Medical Technologies

You’re a university-based researcher, investigator, faculty member or perhaps even a student who has snagged your first funding for the earliest stage commercialization, design and development activities for your potential medical technology. You might even have completed the first activities with that funding and scored $100,000 or more in follow-on funding from GRA, SBIR, or…

The GCMI 2023 State of Medtech Design and Development Report: Part 1

Innovation in medical technologies is something of a paradox. On one hand, new technologies that drive innovation can manifest at breakneck speed. On the other hand, the pace at which those technologies breed innovations that reach full commercialization and patient impact can be glacial by comparison.   What have been the most significant changes with…

THE Place to Start, And Follow-On, For University-Sourced Medtech Innovation Funding

A dive into the Georgia Research Alliance (GRA) and its funding programs with GRA VP of Venture Development Ashley Cornelison In the first of this short series on medtech innovation funding opportunities, GCMI Director of Scientific Affairs Evan Goldberg stated, “GRA is the first place to go for those trying to commercialize a technology out…

The Top Five Medtech and Life Science Funding Sources for GT Faculty, Researchers, Investigators – AT PHASE ZERO

Atlanta is a burgeoning center of medtech and life science innovation. Georgia Tech faculty, researchers and students are measurable contributors to that ecosystem.   Medtech innovation and the commercialization that creates real impact in provision of care, improved outcomes and value is replete with requirements and pitfalls that can doom ideas and technologies with high…

It’s About Time! 2023 BME Spring Capstone Team Aims to Reduce 70% Failure Rate of Common Lumbar Punctures

Lumbar punctures are a procedure performed by neurologists to obtain cerebrospinal fluid from a patient’s back, typically from the L3/L4 spinal canal, and are used for diagnosis and treatment of many neurological diseases and cancers. There are more than 8 million conducted worldwide every year, including 370,000 in the United States.   Currently, doctors feel…

Reducing the 90% Recurrence Rate for Glioblastoma Treatment Through an Implantable Device for the Delivery of Stem Cells

GCMI’s Spring 2023 Capstone Spotlight on Team LifeSTEM “Gliomas are brain tumors that come in multiple forms ranging from low-grade, benign tumors to high-grade, malignant tumors including glioblastomas. Glioblastoma treatment involves surgical resection, chemotherapy, and radiation. However, these tumors are typically incompletely resected, so there is a 90% recurrence rate [for a course of treatment,…

Taking a Bite Out of a 9.5% ORIF Re-Operation Rate

“X-rays supporting our testing at GCMI and T3 Labs clearly showed where the device engaged and the tip aligned at the bone level. This kind of evidence is important for our design history file, something that should make our regulatory journey and overall commercialization pathway more efficient.”